Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed)
The summary for the Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the current Building Infrastructure Leading to Diversity (BUILD) awards. BUILD is part of the Enhancing the Diversity of the NIH-Funded Workforce Program, also known as the Diversity Program Consortium (DPC), consists of three integrated initiatives: BUILD, the National Research Mentoring Network (NRMN) and the Coordination and Evaluation Center (CEC). The purpose of the funding is to allow BUILD sites to continue to implement and evaluate the multi-pronged student, faculty, and institutional interventions to enhance diversity in the NIH biomedical research workforce. In preparation for the second phase of the BUILD initiative, the applicants are expected to provide plans to transition into sustainable models for enhancing diversity in the biomedical research fields at their institutions. Applicants are also expected to develop an effective training, mentoring, or research capacity building intervention that will be disseminated to other institutions to increase the national impact of the initiative.
Federal Grant Title: | Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-RM-18-006 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.310 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | June 11th, 2018 |
Original Application Deadline: | June 11th, 2018 |
Posted Date: | April 3rd, 2018 |
Creation Date: | April 3rd, 2018 |
Archive Date: | July 17th, 2018 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | April 3rd, 2018 |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. see Funding Opportunity for Eligibility Details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-18-006.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
- • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
- • NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
- • Using Metabolomics to Investigate Biological Pathways and Networks (R01)
- • Assay Development for High Throughput Molecular Screening (R21)
- • Membrane Protein Production and Structure Determination (R01)
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)